Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers

Conclusions As a strong CYP3A4 inducer, rifampicin exerted significant effects on the pharmacokinetics of alflutinib and the total active ingredients (alflutinib and AST5902). The results suggested that concomitant strong CYP3A4 inducers should be avoided during alflutinib treatment. This trial was registered athttp://www.chinadrugtrials.org.cn. The registration No. is CTR20191562, and the date of registration is 2019-09-12.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research